Figure 6.

peHLA peptidome originate from tumor-associated genes and includes immunogenic peptides. (A) 4-1BB expression was assayed by FACS analysis of purified naïve CD8⁺ T cells, from healthy HLA-B*35:02 positive donor, following co-culturing with peptide-loaded autologous DCs. Pseudo-color dot plots display the responses for the five HLA peptides and the negative control (cells stimulated with empty DCs). upper numbers in the quadrants show percentages of CD8⁺/4-1BB⁺ cells. (B) The media from restimulated T cells was collected and assessed for the concentration of IFNγ by ELISA. P values were determined by one-way ANOVA test relative to the negative control. n=3, data are represented as mean±SEM *p<0.05, ****p<0.0001. (C) Examples of tumor antigens which are the source of many HLA peptides, including tumor antigens that were identified in the KEGG pathways in cancer database. The antigens are presented with the number of identified peHLA peptides derived from each source protein in each patient (see online supplemental table S9 for the complete list). ANOVA, analysis of variance; DC, dendritic cell; HLA, human leucocyte antigen; peHLA, pleural effusion soluble HLA.